FDA
-
-
-
-
-
-
-
CervoMed shows biomarker improvements in dementia trial
-
-
-
-
-
-
-
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
-
-
-
-
-
-
-
CervoMed reports positive 32-week trial data for dementia drug
-
-
-
-
-
-
-
Brookline Capital Markets Upgrades CervoMed (CRVO) to Buy
-
-
-
-
-
-
-
CervoMed (CRVO) Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
-
-
-
-
-
-
-
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
-
-
-
-
-
-
-
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

